What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2026-05-07 compared with 2025-11-12 · 41 added, 39 removed, 113 unchanged (41% of the section changed)

1 unchanged sentence

Rule 10b5-1 Trading Arrangements

During the three months ended September 30, 2025 , no ne of our directors or officers, as defined in Rule 16a-1(f) of the Exchange Act, adopted or terminated a "Rule 10b5-1 trading arrangement" (as defined in Item 408 of Regulation S-K of the Exchange Act) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

During the three months ended March 31, 2026 , no ne of our directors or officers, as defined in Rule 16a-1(f) of the Exchange Act, adopted or terminated a "Rule 10b5-1 trading arrangement" (as defined in Item 408 of Regulation S-K of the Exchange Act) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

Exhibit Index

17 unchanged sentences

Incorporated by reference Exhibit 4.3 to the Registration Statement on Form S-8 filed on August 5, 2020 (File No.

Amended and Restated Amendment to Development and Option Agreement, dated as of September 28, 2018, by and between CureVac AG and Arcturus Therapeutics Inc.

Incorporated by reference to Exhibit 99.2 to the Company’s Report of Foreign Private Issuer on Form 6-K filed on October 1, 2018 (File No.

Arcturus Therapeutics Ltd.

Amended and Restated Compensation Policy for Company Office Holders.

Incorporated by reference to Exhibit 99.2 to the Company’s Report of Foreign Private Issuer on Form 6-K filed on July 27, 2018 (File No.

Research and Exclusive License Agreement, by and between Arcturus Therapeutics, Inc.

1 unchanged sentence

Incorporated by reference to Exhibit 4.8 to Form 20-F filed on May 14, 2018 (File No.

Research Collaboration and License Agreement, by and between Arcturus Therapeutics, Inc.

and Ultragenyx Pharmaceutical Inc., entered into as of October 26, 2015, as amended October 17, 2017 and April 20, 2018.

Incorporated by reference to Exhibit 4.10 to Form 20-F filed on May 14, 2018 (File No.

Third Amendment to Research Collaboration and License Agreement, by and between Arcturus Therapeutics, Inc.

and Ultragenyx Pharmaceutical Inc., effective June 18, 2019.

Incorporated by reference to Exhibit 10.2 to Form 8-K filed on June 20, 2019 (File No.

Letter Agreement, by and between Arcturus Therapeutics, Inc.

5 unchanged sentences

Incorporated by reference to Exhibit 10.16 to Form 10-Q filed on August 14, 2019.

Development and Option Agreement, by and between Arcturus Therapeutics, Inc.

and CureVac AG, dated January 1, 2018, as amended May 3, 2018.

Incorporated by reference to Exhibit 4.12 to Form 20-F filed on May 14, 2018 (File No.

Third Amendment to Development and Option Agreement, by and between Arcturus Therapeutics, Inc.

and CureVac AG, dated July 26, 2019.

Incorporated by reference to Exhibit 10.20 to Form 10-Q filed on August 14, 2019 (File No.

License Agreement, by and between Arcturus Therapeutics, Inc., as successor-in-interest to Marina Biotech, Inc., and Protiva Biotherapeutics Inc., dated as of November 28, 2012.

Incorporated by reference to Exhibit 4.14 to Form 20-F/A filed on July 10, 2018 (File No.

Patent Assignment and License Agreement, by and between Arcturus Therapeutics, Inc.

and Marina Biotech, Inc., dated as of August 9, 2013.

Incorporated by reference to Exhibit 4.15 to Form 20-F filed on May 14, 2018 (File No.

Share Exchange Agreement, dated as of February 11, 2019, by and between Arcturus Therapeutics Ltd.

and Arcturus Therapeutics Holdings Inc.

Incorporated by reference to Exhibit 10.13 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed on March 18, 2019 (File No.

Amended and Restated Joint Venture, Research Collaboration and License Agreement, dated as of July 14, 2018 by and between Arcturus Therapeutics, Inc.

and Providence Therapeutics, Inc.

Incorporated by reference to Exhibit 10.14 to the Company’s Amendment No.

1 to Annual Report on Form 10-K for the year ended December 31, 2018 filed on April 10, 2019 (File No.

Lease Agreement, by and between Arcturus Therapeutics, Inc.

9 unchanged sentences

Incorporated by reference to Exhibit 10.24 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed on March 16, 2020 (File No.

Manufacturing Support Agreement, dated November 7, 2020, by and between Arcturus Therapeutics Holdings Inc.

and the Economic Development Board of Singapore.

Incorporated by reference to Exhibit 10.33 to Quarterly Report on Form 10-Q filed on November 9, 2020 (File No.

2020 Employee Stock Purchase Plan.

11 unchanged sentences

Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on April 26, 2021 (File No.

Employment Agreement, dated as of June 13, 2019, between the Company and Joseph Payne.

Incorporated by reference to Exhibit 10.1 to Form 8-K12B filed on June 14, 2019 (File No.

Employment Agreement, dated as of June 13, 2019, between the Company and Andy Sassine.

Incorporated by reference to Exhibit 10.2 to Form 8-K12B filed on June 14, 2019 (File No.

Employment Agreement, dated as of June 13, 2019, between the Company and Dr.

Padmanabh Chivukula.

Incorporated by reference to Exhibit 10.3 to Form 8-K12B filed on June 14, 2019 (File No.

2021 Inducement Equity Incentive Plan.

Incorporated by reference to Exhibit 4.1 to Form S-8 filed on October 20, 2021 (File No.

Lease, by and between Arcturus Therapeutics, Inc.

1 unchanged sentence

Incorporated by reference to Exhibit 10.35 to Form 10-Q filed on November 9, 2021 (File No.

Arcturus Therapeutics Holdings Inc.

2021 Inducement Equity Incentive Plan.

Incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-8 filed on October 20, 2021 (File No.

Technology License and Technical Support Agreement, signed July 29, 2021 and effective July 30, 2021, by and between Arcturus Therapeutics, Inc.

and Vinbiotech Research and Manufacture Joint Stock Company.

Incorporated by reference to Exhibit 10.32 to Quarterly Report on Form 10-Q filed on August 10, 2021 (File No.

Framework Drug Substance Supply Agreement, signed July 29, 2021 and effective July 30, 2021, by and between Arcturus Therapeutics, Inc.

and Vinbiotech Research and Manufacture Joint Stock Company.

Incorporated by reference to Exhibit 10.33 to Quarterly Report on Form 10-Q filed on August 10, 2021 (File No.

Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

Incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-8 filed on June 30, 2022.

Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on June 14, 2024 (File No.

Study Support Agreement effective October 31, 2022, by and between Arcturus Therapeutics, Inc.

and Vinbiocare Research and Manufacture Joint Stock Company.

Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on November 4, 2022 (File No.

Cost Reimbursement Contract dated August 31, 2022, by and between Arcturus Therapeutics Holdings Inc.

2 unchanged sentences

Incorporated by reference to Exhibit 10.36 to Quarterly Report on Form 10-Q filed on November 9, 2022 (File No.

Study Support Agreement, dated October 31, 2022, by and between Arcturus Therapeutics, Inc.

and Vinbiocare Research and Manufacture Joint Stock Company.

Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on November 4, 2022 (File No.

Collaboration and License Agreement, dated November 1, 2022, by and between Arcturus Therapeutics Holdings Inc.

20 unchanged sentences

Incorporated by reference to Exhibit 10.32 to Quarterly Report on Form 10-Q filed on November 14, 2023 (File No.

Amendment Number Two to Collaboration and License Agreement, dated March 29, 2024, by and between Arcturus Therapeutics, Inc.

and Seqirus Inc.

Incorporated by reference to Exhibit 10.33 to Quarterly Report on Form 10-Q filed on May 8, 2024 (File No.

Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June 14, 2024 (File No.

First Amendment to Credit Agreement and First Amendment to Revolving Line of Credit, dated June 26, 2024, by and between Arcturus Therapeutics, Inc.

4 unchanged sentences

44, LLC, dated July 12, 2024.

Incorporated by reference to Exhibit 10.36 to Quarterly Report on Form 10-Q filed on May 12, 2025 (File No.

Incorporated by reference to Exhibit 10.36 to Quarterly Report on Form 10-Q filed on November 7, 2024 (File No.

Separation Agreement and General Release between Arcturus Therapeutics Holdings Inc.

and Andy Sassine dated December 11, 2025.

Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on December 15, 2025 (File No.

Employment Agreement between Arcturus Therapeutics Holdings Inc.

and Joe Roberts dated July 3, 2018.

Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed on December 15, 2025 (File No.

Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended.

4 unchanged sentences

Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

The following financial statements and footnotes from the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025 formatted in Inline Extensible Business Reporting Language (Inline XBRL):

The following financial statements and footnotes from the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 formatted in Inline Extensible Business Reporting Language (Inline XBRL):

101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

12 unchanged sentences

ARCTURUS THERAPEUTICS HOLDINGS INC.

November 12, 2025

/s/ Andy Sassine

Chief Financial Officer

Principal Financial and Accounting Officer

/s/ Joseph Roberts

Joseph Roberts

Interim Principal Finance and Accounting Officer, Controller

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information